Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Niue Health Report.
Press releases published on April 25, 2025
Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees
GlobeNewswire
·
April 25, 2025
FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company that it has not paid certain fees …
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
GlobeNewswire
·
April 25, 2025
FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new research intended to improve the care of patients with cutaneous and …
Prelude Announces Presentations at 2025 AACR Annual Meeting
GlobeNewswire
·
April 25, 2025
Preclinical data elucidating the mechanism of action of PRT3789, Prelude’s first-in-class, highly selective SMARCA2 degrader currently in early clinical development Highlights from Prelude’s efforts to discover and develop selective KAT6A degraders, …
SRx Health Solutions, Inc. (formerly known as Better Choice Company Inc.) Announces Halo Spin-Out Distribution for Stockholders of Record as of April 23, 2025
GlobeNewswire
·
April 25, 2025
TAMPA, Fla., April 25, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (formerly known as Better Choice Company Inc.) (NYSE American: BTTR) (the “Company”), a leading global health and wellness company, today announced that it will distribute (the “ …
Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025
GlobeNewswire
·
April 25, 2025
Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co- …
Clenbuterol Bodybuilding (Clen) Pills, Clenbuterol Dosage, Clenbuterol, Benefits, Clenbuterol Side Effects, Clenbuterol Cycles, Where to buy Clenbuterol tablet buy, ambroxol, lavizoo (CrazyBulk)
GlobeNewswire
·
April 25, 2025
New York City, April 25, 2025 (GLOBE NEWSWIRE) -- Why Do People Look for Weight Loss Pills? Many people want a leaner body and look for pills to help them achieve this. One such pill is Clenbuterol, which is often used for weight loss. However, Clenbuterol …
Best Probiotics For Women: Top-Rated Picks for Digestion, Mood, and Immunity Announced By WhatBest.
GlobeNewswire
·
April 25, 2025
New York, April 25, 2025 (GLOBE NEWSWIRE) -- WhatBest, a leading authority known for meticulous, research-based evaluations of health and wellness products, is excited to announce its comprehensive list of the best probiotics specifically chosen for women. …
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
GlobeNewswire
·
April 25, 2025
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity - Combination …
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
GlobeNewswire
·
April 25, 2025
Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 VANCOUVER, British Columbia, April …
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
GlobeNewswire
·
April 25, 2025
Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour BRAF degrader demonstrates broad activity across all three BRAF mutation classes Aurora A kinase …
Enable Injections Presents Survey Results Highlighting Missed Opportunities in Subcutaneous Oncology Drug Development at AACR 2025
GlobeNewswire
·
April 25, 2025
CINCINNATI, April 25, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug delivery platform, announced today the presentation of a poster featuring new findings …
Best SARMs for Bulking, Cutting, Fat Loss & Muscle Growth: Top Selective Androgen Receptor Modulators Reviewed for Lean Gains & Shredded Physique From CrazyBulk
GlobeNewswire
·
April 25, 2025
New York City, April 25, 2025 (GLOBE NEWSWIRE) -- In recent years, SARMs have become a go-to solution for fitness enthusiasts seeking enhanced performance, lean muscle growth, and effective fat loss—without the risks associated with anabolic steroids. As …
Juvent Launches Next Generation Bone Health Supplement HydroxyBMD3 at the National Bone Health & Osteoporosis Foundation (BHOF) Symposium in Washington, DC
GlobeNewswire
·
April 25, 2025
OOLTEWAH, Tenn., April 25, 2025 (GLOBE NEWSWIRE) -- Juvent, an innovator in clinically validated bone and musculoskeletal health solutions, debuted its revolutionary new supplement system HydroxyBMD3 at the National Bone Health …
Press release: Transparency Notification from Shareholders
GlobeNewswire
·
April 25, 2025
Transparency Notification from Shareholders Ghent, Belgium – 25 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and …
Le Parlement est en pleine campagne « poil » itique : Le vote est ouvert pour le concours photo « Les animaux de compagnie les plus mignons sur la Colline du Parlement »
GlobeNewswire
·
April 25, 2025
OTTAWA, 25 avr. 2025 (GLOBE NEWSWIRE) -- L’Institut canadien de la santé animale (ICSA) est ravi d’annoncer que le vote du public est maintenant ouvert pour le 3e concours annuel de photos « Les animaux les plus mignons sur la Colline du Parlement »! Les …
Mental Health Nonprofit Queer LifeSpace to Host Annual Fundraising Gala "Pride Renaissance: Celebrating Community Resilience"
GlobeNewswire
·
April 25, 2025
SAN FRANCISCO, April 25, 2025 (GLOBE NEWSWIRE) -- In the midst of a worsening mental health crisis and rising anti-LGBTQIA+ attacks nationwide, nonprofit counseling agency Queer LifeSpace will host its largest-ever fundraiser on Friday, May 30th, rallying …
Bassett Medical Center Earns Prestigious Magnet Designation for Nursing Excellence
GlobeNewswire
·
April 25, 2025
Cooperstown, New York, April 25, 2025 (GLOBE NEWSWIRE) -- Bassett Medical Center in Cooperstown, NY, has achieved Magnet® Recognition for Nursing Excellence, the highest national honor a hospital can attain for nurse satisfaction, patient outcomes, and …
Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.)
GlobeNewswire
·
April 25, 2025
ORION OYJ PÖRSSITIEDOTE / SUURIMMAT OSAKKEENOMISTAJAT -TIEDOTE 25.4.2025 KLO 17.20 Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.) Orion Oyj on saanut Arvopaperimarkkinalain 9. luvun 5 §:n …
CHMP recommends EU approval for Duvyzat to treat Duchenne muscular dystrophy
GlobeNewswire
·
April 25, 2025
Recommendation is based on Phase 3 EPIDYS trial data that demonstrated Duvyzat (givinostat) provides statistically and clinically meaningful treatment benefits in individuals with Duchenne muscular dystrophy (DMD) If approved by the European Commission, …
Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)
GlobeNewswire
·
April 25, 2025
Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical …